GENE ONLINE|News &
Opinion
Blog

BMS
BMS to Sell 60% Stake in China JV SASS, Marking a Four-Decade Turning Point
2025-09-18
Bristol Myers Squibb Bets Big on America with $40 Billion Investment Plan
2025-05-07
Bristol Myers Scores FDA Approval for Opdivo-Yervoy Combination as First-Line HCC Therapy
2025-04-14
Novartis Invests $745M to Compete with BMS and Lilly in the Radiopharma Race
2024-11-19
Big Pharma’s Next Move: BMS, Merck, Amgen Eye M&A to Tackle Patent Expirations
2024-11-14
Bristol Myers Squibb’s 2024 Surge: Revenue Growth, Regulatory Wins, and Strategic Overhaul
2024-06-25
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
Dividend Exchange Rate for Q3 2025 Announced by DEC on March 12, 2026
2026-03-12
NewHydrogen Files International Patent Application for ThermoLoop Technology to Enhance Hydrogen Production Efficiency
2026-03-12
BioGene Therapeutics Inc. Appoints Raj S. Pruthi as Director
2026-03-12
Scroll to Top